Tuesday
Apr 23, 2013
|
|
08:30AM
|
05:15PM
|
Breakout Sessions and International Case Studies
|
Breakout Sessions
|
|
|
08:45AM
|
09:00AM
|
Orphan Disease Forum Welcoming Remarks
|
Orphan Disease Forum
|
Building: N426 C
|
|
09:00AM
|
11:30AM
|
Collaborating For Solutions: Public-Private Partnerships in Agricultural Development for Food Security
|
Food and Agriculture Track
|
Building: S404D
|
|
09:00AM
|
10:15AM
|
And Now for Something Completely Different: How Will Pharma Access External Early-Stage Innovation?
|
Drug Discovery and Development Track
|
Building: S401A
|
|
09:00AM
|
10:15AM
|
Breakthrough Therapies: Navigating the Expedited Development Process
|
Manufacturing of Biologics and Drugs Track
|
Building: N426A
|
|
09:00AM
|
10:15AM
|
Bridging the Productivity Gap: Big Pharma Strategies for Accessing Early-Stage Innovation
|
Business Development Track
|
Building: N427BC
|
|
09:00AM
|
09:45AM
|
Can Israel Become the Next Biotech Start-Up Nation?
|
International Market Briefings Track
|
Building: S101A
|
|
09:00AM
|
10:15AM
|
Choosing Both: Crop Engineering to Enable both Food and Fuel
|
Biofuels and Biobased Chemicals Track
|
Building: N427D
|
|
09:00AM
|
10:15AM
|
200 New Therapies and Means to Diagnose Most Rare Diseases by 2020: Collaboration Toward Ambitious Goals
|
Orphan Disease Forum
|
Building: N426C
|
|
09:00AM
|
10:15AM
|
Embracing the Digital World: Finding Your Online Voice in Advocacy
|
Market Access and Commercialization Track
|
Building: S403B
|
|
09:00AM
|
10:15AM
|
Engaging with Chicago Area Multinational Biopharma
|
International Spotlights & Policy Track
|
Building: S101B
|
|
09:00AM
|
10:15AM
|
Impact Investing: An Alternative to Traditional Venture Capital and Non-Dilutive Grants?
|
Finance Track
|
Building: N426B
|
|
09:00AM
|
10:15AM
|
Medical Countermeasures: Partnering with the FDA for Successful Product Development
|
Achieving Regulatory Approval and Compliance Track
|
Building: S402B
|
|
09:00AM
|
10:15AM
|
Multi-Party and Cross-Border Patent Issues Affecting Biotech Businesses
|
Biotech Patenting and Tech Transfer Track
|
Building: S404A
|
|
09:00AM
|
10:00AM
|
The Changing Landscape for Companion Diagnostic Deals
|
Personalized Medicine and Diagnostics Forum
|
Building: S404BC
|
|
09:00AM
|
05:00PM
|
Personalized Medicine and Diagnostics Forum
|
Breakout Sessions
|
|
|
09:00AM
|
10:15AM
|
New Defenses Against Old Enemies: Vaccines and Biotherapies for Bacterial Infection
|
Innovations and Opportunities in Vaccines
|
Building: S402A
|
|
10:00AM
|
10:45AM
|
Canadian Financial Incentives Spur Research and Development
|
International Market Briefings Track
|
Building: S401BCD
|
|
10:15AM
|
11:30AM
|
Companion Diagnostics: Demonstrating Value and Delivering Success
|
Personalized Medicine and Diagnostics Forum
|
Building: S404BC
|
|
10:30AM
|
11:30AM
|
Massive Health Care Consolidation and Its Impact on Biotech
|
Market Access and Commercialization Track
|
Building: S403B
|
|
10:30AM
|
11:30AM
|
Austerity vs. Growth: Will the Life Sciences Be the Next European Bailout?
|
International Spotlights & Policy Track
|
Building: S102A
|
|
10:30AM
|
11:30AM
|
Increasing Access to Medicines: Regulatory Approval Systems in Emerging Markets
|
International Spotlights & Policy Track
|
Building: S101B
|
|
10:30AM
|
11:30AM
|
Affinity and Beyond: The Future of Separation Technologies
|
Manufacturing of Biologics and Drugs Track
|
Building: S402B
|
|
10:30AM
|
11:30AM
|
Money Ball: Winning Venture Strategies
|
Finance Track
|
Building: N426B
|
|
10:30AM
|
11:30AM
|
Myriad, Mayo, and Beyond: Developments in the Law of Patentable Subject Matter
|
Biotech Patenting and Tech Transfer Track
|
Building: S404A
|
|
10:30AM
|
11:30AM
|
adVENTURES in Academic Partnering
|
Business Development Track
|
Building: N427BC
|
|
10:30AM
|
11:30AM
|
Russia’s Drug Development Outlook
|
Drug Discovery and Development Track
|
Building: S401 A
|
|
10:30AM
|
11:30AM
|
Say What????: Understanding “Regulatory Speak” & Best Practices for Optimizing FDA-Sponsor Communication
|
Achieving Regulatory Approval and Compliance Track
|
Building: N426A
|
|
10:30AM
|
11:45AM
|
Orphan and Rare Diseases: Closing Distances in Understanding Larger Disease Mechanisms
|
Orphan Disease Forum
|
Building: N426C
|
|
11:00AM
|
11:45AM
|
Government Initiatives in New Drug Development in South Korea
|
International Market Briefings Track
|
Building: S101A
|
|
02:15PM
|
03:00PM
|
Market Access in Europe – Pricing in Germany and its Impact on Other Countries
|
International Market Briefings Track
|
Building: S101A
|
|
02:30PM
|
03:30PM
|
I Didn’t Know Vaccines Could Do That: Reinventing the Classic Vaccine Approach
|
Innovations and Opportunities in Vaccines
|
Building: S402A
|
|
02:30PM
|
03:30PM
|
Corporate Venture Capital in the AgTech Entrepreneurial Ecosystem
|
Food and Agriculture Track
|
Building: S404D
|
|
02:30PM
|
03:30PM
|
Economic Impact of Implementing a National Serialization and Traceability System
|
Manufacturing of Biologics and Drugs Track
|
Building: S402B
|
|
02:30PM
|
03:30PM
|
Fashion or Innovation?: Learning From Trends in Dealmaking Over the Past Decade
|
Business Development Track
|
Building: N427BC
|
|
02:30PM
|
03:30PM
|
How to Adapt: International Consortium Lays Groundwork for Adaptive Licensing
|
International Spotlights & Policy Track
|
Building: S101B
|
|
02:30PM
|
03:30PM
|
Assessment of PDUFA and FDASIA Implementation: How the Changes are Impacting the Work of Prescription Drug Regulatory Professionals
|
Achieving Regulatory Approval and Compliance Track
|
Building: N426A
|
|
02:30PM
|
03:30PM
|
Open Innovation: Transforming the Model of Biopharmaceutical R&D
|
Drug Discovery and Development Track
|
Building: S401BCD
|
|
02:30PM
|
03:30PM
|
Policy Changes to Advance Personalized Medicine
|
Personalized Medicine and Diagnostics Forum
|
Building: S404BC
|
|
02:30PM
|
03:30PM
|
The Compulsory Licensing Trend: Increased Access, or Lost Opportunities and Unintended Consequences?
|
Biotech Patenting and Tech Transfer Track
|
Building: S404A
|
|
02:30PM
|
03:30PM
|
Survival Strategies for Companies Under $100M Market Cap: Routes to Equity and Exits for Micro-Cap Companies
|
Finance Track
|
Building: N426B
|
|
02:30PM
|
03:30PM
|
Survival Strategies in the New Individual Patient-Centered Marketplace
|
Orphan Disease Forum
|
Building: N426C
|
|
02:30PM
|
03:30PM
|
Sustainability Standards: Why One Size Should Fit All in the Global Marketplace
|
Biofuels and Biobased Chemicals Track
|
Building: N427D
|
|
02:30PM
|
03:30PM
|
ROI: The Economic Impact of Federal Drug Discount and Rebate Programs on Biologic Products
|
Market Access and Commercialization Track
|
Building: S403B
|
|
03:15PM
|
05:00PM
|
Regulatory Review and Market Uptake of Biosimilars: The European Experience
|
International Market Briefings Track
|
Building: S101A
|
|
03:45PM
|
05:00PM
|
Challenges and Opportunities for Small Companies in AgBiotech: Collaborating and Competing with the Majors
|
Food and Agriculture Track
|
Building: S404D
|
|
03:45PM
|
05:00PM
|
Broad-Spectrum Antivirals: The “New” Holy Grail
|
Drug Discovery and Development Track
|
Building: S401A
|
|
03:45PM
|
05:00PM
|
Biosimilars: Strategic Considerations for Regulatory Approval and Patents under the BPCIA
|
Achieving Regulatory Approval and Compliance Track
|
Building: N426A
|
|
03:45PM
|
05:00PM
|
Demonstrating Product Economic and Clinical Value: Know What Investors are Looking For
|
Market Access and Commercialization Track
|
Building: S403B
|
|
03:45PM
|
05:00PM
|
Emerging Markets Heads of Patent Offices Discussion
|
Biotech Patenting and Tech Transfer Track
|
Building: S404A
|
